Tag Archives: MS

July, 2016

  • 20 July

    An Antibody-Based Drug for Multiple Sclerosis

    Inserm Unit U919, directed by Prof. Denis Vivien (“Serine Proteases and Physiopathology of the Neurovascular Unit”) has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed by Fabian Docagne and published in Brain, paves the way for a new strategy to control the disease. Multiple sclerosis …

  • 1 July

    Genentech’s Ocrelizumab Granted Priority Review as First Potential Therapy for PPMS

    SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company’s Biologics License Application (BLA) for OCREVUS™ (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple …

June, 2016

  • 8 June

    Biogen’s Multiple Sclerosis Drug Misses Main Goal in its Phase 2 Study

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent …

May, 2016

  • 4 May

    Biogen to Spin Off Hemophilia Business into Separate Company

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (NASDAQ: BIIB) today announced that it intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise. “We …

April, 2016

March, 2016

January, 2016

  • 13 January

    The MS Game Changer

    A new medication for multiple sclerosis made waves when research about its effectiveness debuted at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) back in October 2015. Now experts are calling this medication one of the greatest developments of the past year for the …

  • 4 January

    Teva and Active Biotech Discontinue Trials Evaluating Higher Doses of Oral MS Drug

    JERUSALEM & LUND, Sweden–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ Stockholm:ACTI) today announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients. The change comes …

December, 2015

October, 2015